2024-05-03 00:35:24 ET
Vir Biotechnology, Inc. (VIR)
Q1 2024 Earnings Conference Call
May 02, 2024, 04:30 PM ET
Company Participants
Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer
Marianne De Backer - Chief Executive Officer
Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer
Sung Lee - Chief Financial Officer
Conference Call Participants
Gena Wang - Barclays
Paul Choi - Goldman Sachs
Alec Stranahan - Bank of America
Phil Nadeau - TD Cowen
Patrick Trucchio - H.C. Wainwright
Rosa Chen - Leerink Partners
Joseph Stringer - Needham & Company
Eric Joseph - JP Morgan
Michaels Ulz - Morgan Stanley
Presentation
Operator
Hello. Welcome to Vir Biotechnology’s First Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session.
I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer. You may begin, Ms. Damouni Ellis.
Sasha Damouni Ellis
Thank you, and good afternoon. With me today are Dr. Marianne De Backer, Chief Executive Officer; Dr. Carrie Huang, Senior Vice President, Clinical Research and Interim Chief Medical Officer; and Sung Lee, Executive Vice President and Chief Financial Officer.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements, to differ significantly from those expressed or implied by such forward looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including forms 10-K, 10-Q and 8-K....
Read the full article on Seeking Alpha
For further details see:
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript